Ballester Pura, Espadas Cristina, Almenara Susana, Barrachina Jordi, Muriel Javier, Ramos Enrique, Toral Natalia, Belda César, Peiró Ana M
Pharmacology Department, Pharmacy Degree, San Antonio Catholic University, 30107 Murcia, Spain.
Bioengineering Institute, Pediatrics and Organic Chemistry Department, Miguel Hernández University of Elche (UMH), 03202 Alicante, Spain.
Pharmaceuticals (Basel). 2023 Jul 3;16(7):954. doi: 10.3390/ph16070954.
The long-term use of psychopharmacology medications in autism spectrum disorder (ASD) hitherto remains controversial due to a lack of evidence about safety and tolerability. In this regard, genotyping the metabolizing enzyme cytochrome P450 , especially its extreme phenotypes, could help to prevent drug-related adverse reactions or adverse events (AEs). There are several medications warranting screening that are consumed by people with ASD, such as risperidone and aripiprazole to name a few. A naturalistic observational study was carried out in participants with ASD to analyze the influence of the phenotype in drug tolerability using a local pharmacovigilance system created for this study. In this case, AEs were identified from participants' electronic health records (EHRs) and paper registries. Other variables were collected: socio-demographic information, comorbidities, and psychopharmacology prescriptions (polypharmacy defined as ≥4 simultaneous prescriptions) and doses. The genetic analysis included allelic discrimination (*1, *2, *3, *4, *5, *6, *10, *17, and *41) and copy number variations. All of these were used to determine theoretical phenotypes of the metabolic profiles: poor (PM); intermediate (IM); normal (NM); and ultra-rapid (UM). Sex differences were analyzed. A total of 71 participants (30 ± 10 years old, 82% male, 45% NM phenotype (32 participants)) with a median of 3 (IQR 2-4) comorbidities per person, mainly urinary incontinence (32%) and constipation (22%), were included. UM showed the highest rate of polypharmacy, whilst, IM participants had the highest rates of neurological and psychiatric AEs, even worse if a inhibitor drug was prescribed simultaneously. pharmacogenomics and the monitoring of new antipsychotic prescriptions may make a difference in medication safety in adults with ASD. Particularly in those with psychopharmacology polymedication, it can help with AE avoidance and understanding.
由于缺乏关于安全性和耐受性的证据,迄今为止,在自闭症谱系障碍(ASD)中使用精神药理学药物进行长期治疗仍存在争议。在这方面,对代谢酶细胞色素P450进行基因分型,尤其是其极端表型,有助于预防药物相关的不良反应或不良事件(AE)。有几种ASD患者使用的药物值得进行筛查,如利培酮和阿立哌唑等。本研究通过为该研究创建的本地药物警戒系统,对ASD参与者进行了一项自然观察性研究,以分析表型对药物耐受性的影响。在这种情况下,从参与者的电子健康记录(EHR)和纸质登记中识别AE。还收集了其他变量:社会人口统计学信息、合并症、精神药理学处方(多药治疗定义为≥4种同时开具的处方)和剂量。基因分析包括等位基因鉴别(*1、*2、*3、*4、*5、*6、*10、17和41)和拷贝数变异。所有这些都用于确定代谢谱的理论表型:慢代谢型(PM);中间代谢型(IM);正常代谢型(NM);和超快代谢型(UM)。分析了性别差异。总共纳入了71名参与者(年龄30±10岁,82%为男性,45%为NM表型(32名参与者)),每人合并症中位数为3(四分位间距2 - 4),主要为尿失禁(32%)和便秘(22%)。UM显示多药治疗率最高,而IM参与者的神经和精神AE发生率最高,如果同时开具抑制剂药物,情况会更糟。药物基因组学和新抗精神病药物处方的监测可能会对ASD成人患者的用药安全产生影响。特别是对于那些使用多种精神药理学药物的患者,它有助于避免AE并增进理解。